Mar 3, 2026 07:00AM
Mar 3, 2026 07:00AM
Feb 10, 2026 06:52AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Sep 3, 2025 01:01PM
Sep 3, 2025 01:01PM
Apr 21, 2025 07:02AM
Apr 21, 2025 07:00AM
Nov 12, 2024 07:00AM Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
Oct 28, 2024 09:25AM
Oct 28, 2024 09:25AM
Sep 18, 2024 07:30AM
Sep 18, 2024 07:30AM
Sep 11, 2024 06:36AM
Sep 9, 2024 07:02AM
Sep 9, 2024 07:00AM Roivant Provides Update on Graves’ Disease Development Program
Aug 8, 2024 07:00AM
May 30, 2024 07:00AM
Feb 13, 2024 07:00AM
Nov 13, 2023 07:00AM
Nov 10, 2023 08:03AM
Nov 10, 2023 08:00AM
Aug 14, 2023 07:00AM Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
Jul 11, 2023 08:00AM
Jun 28, 2023 08:57AM
Jun 28, 2023 07:00AM
May 16, 2023 07:02AM
May 16, 2023 07:00AM
Mar 15, 2023 07:46AM
Mar 15, 2023 07:45AM Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Mar 15, 2023 07:45AM
Mar 15, 2023 07:45AM
Feb 22, 2023 06:52AM
Feb 21, 2023 08:32PM
Feb 21, 2023 08:32PM
Nov 14, 2022 07:00AM
Nov 14, 2022 07:00AM Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
Aug 15, 2022 07:00AM
Aug 15, 2022 07:00AM
Jun 28, 2022 06:11AM
Jun 28, 2022 06:10AM
Jun 28, 2022 06:10AM
May 25, 2022 05:59AM
May 24, 2022 08:21AM "VTAMA Has Blockbuster Potential" - Cantor Fitzgerald Bullish on Roivant Sciences (ROIV) Following Dermavant’s Drug Approval
May 24, 2022 06:01AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All